STATISTICA® StatSoft, Inc. (StatSoft Scandinavia AB, Uppsala, Sweden) 9.0 software package was used MAPK inhibitor for all statistical analyses. Positively skewed variables were logarithmically transformed prior to analysis. Values are presented as mean ± SD. The

study was approved by the Ethics Committee at Huddinge University Hospital, Stockholm, Sweden. The research was performed in accordance with institutional guidelines of the Karolinska Institute and in accordance with the Declaration of Helsinki. All subjects gave their informed consent. As shown in Table 1, the level of ascorbate in plasma increased significantly after treatment with ascorbate. Likewise, the level of α-tocopherol in plasma increased after treatment with vitamin E, whereas measured levels of retinol remained unchanged. As shown in Table 2, inhalation of cigarette smoke induced a significant reduction in capillary blood flow velocity. This effect of smoking was very prompt both before (p < 0.0007) and after treatment with ascorbate (p < 0.0004). However, there was no significant difference in terms of relative reduction in CBV before or after intervention by either of the antioxidants. The reduction was 65% before ascorbate and 60% after ascorbate (ns). At baseline, TtP was significantly prolonged after inhalation of cigarette smoke, an increase in TtP from 7.3 to 10.6 seconds (p < 0.05). When comparing

the response to provocation by PRH before and after two weeks of treatment with ascorbate, there was a highly significant shortening of TtP Atezolizumab datasheet as compared with baseline: 7.3 seconds vs 5.2 seconds (p < 0.002). Furthermore, the TtP in response to smoking after treatment with ascorbate was prolonged from 5.2 to 7.4 seconds (p < 0.002). The relative change in response to smoking did not differ between subjects treated or not treated with ascorbate (ns). The same experimental protocol was repeated in volunteers using vitamin E. Again, there was an effect on resting CBV with a similar effect of acute smoke inhalation on CBV as for ascorbate. The reduction in CBV after smoking was highly significant: from 0.72 ± 0.24 to 0.40 ± 0.22 mm/sec (p < 0.000008). Concordant with the results of treatment

with ascorbate, there was no difference Arachidonate 15-lipoxygenase in the response of CBV to the effects of smoke inhalation before and after treatment with vitamin E, i.e., it was not possible to demonstrate any significant effect on the reduction in CBV in response to smoking before or after the two-week treatment with vitamin E. The baseline TtP before treatment with vitamin E was similar to before ascorbate, 7.0 ± 3.0 seconds compared to 7.3 seconds (ns). However, there was no difference in TtP before or after the two-week treatment with vitamin E, 7.0 ± 3.0 seconds vs 6.8 ± 2.6 seconds (ns). Baseline CBV before either treatment did not differ (ns). In contrast to baseline measurements, the CBV increased significantly after treatment with ascorbate, from 0.64 ± 0.33 to 1.00 ± 0.53 mm/sec (p < 0.